Synairgen (GB:SNG) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Synairgen plc has announced the retirement of Chairman Simon Shaw and the appointment of Mark Parry-Billings as his successor after the upcoming AGM on October 10, 2024. Parry-Billings brings over 30 years of experience in biotech and pharmaceuticals, notably in respiratory therapeutics, to Synairgen, a company focused on developing SNG001, an inhaled antiviral treatment for severe viral lung infections.
For further insights into GB:SNG stock, check out TipRanks’ Stock Analysis page.
